Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07086677 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
A Phase 1 study of Streptococcus Pneumoniae, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 372
- Enrollment target
- 5
- Study locations
NCT07086677: Recruiting Phase 1 study of Streptococcus Pneumoniae, sponsored by Pfizer.
NCT07086677 is a Phase 1 study of Streptococcus Pneumoniae that is actively recruiting participants, run by Pfizer. The registered enrollment target is 372 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (520% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07086677, a Phase 1 study of Streptococcus Pneumoniae, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 372 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to two doses of study vaccine or comparator and take part in follow-up visits. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during clinic visits.
Primary Outcome
Prespecified local reactions (redness, swelling, and pain at the injection site) occurring within 7 days of each dose administered in the study.
Conditions Studied
Interventions
- BIOLOGICAL PG4 vaccine in Buffer 1 with low dose PA-001
- BIOLOGICAL PG4 in Buffer 1 with low dose PA-002
- BIOLOGICAL PG4 in Buffer 1 with high dose PA-001
- BIOLOGICAL PG4 vaccine in Buffer 1 with high dose PA-002
- BIOLOGICAL PG4 vaccine in Buffer 2
Study Locations (5)
California
- Orange County Research Center - Lake Forest
Florida
- Indago Research & Health Center, Inc - Hialeah
Kansas
- Johnson County Clinical Trials - Lenexa
Nebraska
- Velocity Clinical Research, Omaha - Omaha
Ohio
- CTI Clinical Research Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2027-09-23 |
| Phase | Phase 1 |
What NCT07086677 shows while recruiting
NCT07086677 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (520% higher).
The record links to 1 condition, with Streptococcus Pneumoniae appearing as the primary indexed condition, and to 5 interventions - of which PG4 vaccine in Buffer 1 with low dose PA-001 is the first listed.
NCT07086677 lists 5 locations in 5 states (California, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT07086677 about?
NCT07086677 is a clinical study titled "A Study to Learn About How a New Pneumococcal Vaccine Works in Adults". The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but l...
What is the current status of trial NCT07086677?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 372 participants. The study started on 2025-07-22. Estimated completion is 2027-09-23.
What conditions does trial NCT07086677 study?
This clinical trial studies the following conditions: Streptococcus Pneumoniae.
What interventions are being tested in trial NCT07086677?
The interventions under investigation include: PG4 vaccine in Buffer 1 with low dose PA-001 (BIOLOGICAL), PG4 in Buffer 1 with low dose PA-002 (BIOLOGICAL), PG4 in Buffer 1 with high dose PA-001 (BIOLOGICAL), PG4 vaccine in Buffer 1 with high dose PA-002 (BIOLOGICAL), PG4 vaccine in Buffer 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07086677?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07086677 being conducted?
This trial has 5 study locations across California, Florida, Kansas, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Streptococcus Pneumoniae
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07086677's enrollment target sits among peer trials
372 85th of 2000 higher than 1,916 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI